An interventional study of 50 cm BP limb length and 100 cm BP limb length in Obesity, Morbid, Metabolic Syndrome and NASH - Nonalcoholic Steatohepatitis, sponsored by University of Missouri-Columbia. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by University of Missouri-Columbia · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.
Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 5th largest by planned enrollment of the 150 interventional ones that give a count, is one of 10 that started in 2021, is one of 107 with no phase, reaches primary completion later than 33 of the 34 other live ones, and was the 172nd registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18–90
The Cleveland Clinic · Sites in United States
Ages 18–70
University of Maryland, Baltimore · Sites in United States
Ages 18+ · Women only
University of Missouri-Columbia · Sites in United States
Ages 18+
Salvador Navarrete · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 11 · Phase 3 8 · Phase 4 13
First in 1980; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 39 across the 150 interventional studies, 50 across the 63 observational. Of the 147 that completed or were terminated, 56 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 213 have an industry lead sponsor. The 10 most frequent:
University of Missouri-Columbia is the lead sponsor of 365 studies on the registry; 69 are open to participants now.
Of its 43 completed or terminated interventional studies of FDA-regulated products, 29 (67%) have results posted.
University of Missouri-Columbia has 5 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
8 of the studies in Obesity, Morbid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06199154University of Maryland, BaltimoreInduction of Labor in Morbidly Obese Patients | 2026-12 |
| NCT05711758Christopher C. Thompson, MD, MScEfficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure | 2026-12 |
| NCT02602769Columbia UniversityWhole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome | 2026-12 |
| NCT05215886University of California, DavisCognitive Impairment, Obesity, and the Effects of Bariatric Surgery | 2026-12-31 |
| NCT03868592Mayo ClinicLong-term, Substantial Weight Loss and Insulin Regulation of Lipolysis | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 213 studies in Obesity, Morbid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Variable outcomes after weight loss surgery are likely attributable to complex, poorly understood mechanisms. Due to the significant impact that morbid obesity has on a patient's health, successful management of obesity and its related comorbid medical conditions is important and thus necessitates continued improved therapies for treating obesity. Although the mechanisms of weight loss after surgical intervention are poorly understood, improved understanding of molecular and metabolic changes that occur after weight loss surgery may offer the ability to provide targeted precision therapy for patients with morbid obesity undergoing surgical therapy. In this proposal, the investigators will combine a clinical trial whereby modifications to the gold-standard for weight loss surgery, the gastric bypass, are evaluated while simultaneously measuring molecular and metabolic changes that occur in response to these weight loss procedures. Through creating variable lengths of bypass intestine after gastric bypass, the investigators will be able to determine the effect of malabsorption on clinical outcomes and mechanisms involved in weight loss after gastric bypass. The investigators will also use two control groups. One will be a surgical weight loss control group and consist of patients undergoing a laparoscopic sleeve gastrectomy, a non-intestinal bypass procedure. The other group will consist of patients having non-surgical weight loss therapy. To asses metabolic changes that occur in response to surgical weight therapy and specifically intestinal bypass and malabsorption, the investigators will examine changes in the gut microbiome and plasma gut enteroendocrine hormones. To evaluate molecular pathways that are impacted as a result of gastric bypass and malabsorption, the investigators will measure circulating microRNAs (miRNAs) in the blood. Measurement of miRNAs will provide data on an easily measurable molecular marker for each treatment group. This is a first step in translational exploration of mechanisms of weight loss after surgery by evaluating both clinical and molecular/metabolic outcomes and begin an explorative process towards creating an individualized approach to improving outcomes after weight loss surgery.
Outcomes after weight loss surgery are quite variable with some patients regaining a significant amount of weight in the postoperative period. Increasing evidence suggests gastric bypass leads to weight loss and improvement in associated metabolic illness through mechanisms other than just restriction and malabsorption and may include circulating bile acids, gut hormones, genetic/epigenetic variability, changes in gut microbiota as well as other mechanisms. Whether modifications to bypassed intestine length may improve outcomes after gastric bypass has not been adequately studied with inconsistent results in the literature. Whether increasing the amount of bypassed intestine may positively amplify the multi-factorial mechanisms involved in successful weight loss has not been studied.
The primary goal of the research is to determine if increasing the amount of bypassed intestine during gastric bypass surgery improves outcomes and effects molecular and metabolic changes that may impact outcomes after gastric bypass. The proposed research will evaluate not only biologic mechanisms of weight loss and correlation between these mechanisms and successful weight loss but also investigate the role intestinal bypass has on molecular and metabolic mechanisms involved in effective weight loss therapy. Regardless if weight loss outcomes are similar in patients with different lengths of bypassed intestine, the role of the gut in gastric bypass will be investigated through evaluation of gut microbiota, circulating miRNAs and gut hormones, three mechanisms thought to play a role in the effectiveness of the gastric bypass for weight loss surgery.
Aim 1: Determine if increasing length of bypassed intestine leads to improved clinical outcomes after gastric bypass. A randomized-controlled trial design will be used with patients randomized to variable lengths of bypassed intestine when undergoing gastric bypass. A randomized trial will help avoid procedure selection bias. Surgical and non-surgical control groups will consist of patients having sleeve gastrectomy (non-intestinal bypass surgical control) and those undergoing best non-surgical, medical therapy. Primary outcomes measured will include weight loss and relief of medical comorbidities of obesity specifically diabetes and dyslipidemia. Secondary outcomes include complications related to malabsorption.
Aim 2: Measure gut hormone changes after increased intestinal bypass during gastric bypass. The investigators will measure gut hormones after variable amounts of intestinal bypass to determine the role of intestinal bypass in improvement of gut hormone production that affects metabolism, hunger and possibly weight loss. Blood collected from patient's in Aim 1 will be used to measure gut hormone levels which will then be correlated to clinical outcomes.
Aim 3: miRNA profiling in patients having gastric bypass with variable intestinal bypass lengths. The investigators will perform miRNA arrays on plasma from patients from Aim 1 to determine possible pathways impacted by weight loss and in particular increased intestinal bypass lengths in patients undergoing gastric bypass. The variable expression of miRNA will also be correlated to weight loss outcomes and metabolic disease improvement in the surgical patients.
Aim 4: Measure variation in gut microbiome due to increased intestinal bypass during gastric bypass. The investigators will examine the impact of weight loss and variable intestinal bypass lengths during gastric bypass on the gut microbiome. This will be determined through collection of stool samples preoperatively as well as postoperatively in patients having weight loss surgery. Samples will be collected from patients in Aim 1 above. Sleeve gastrectomy patients will be used to determine the impact of surgical weight loss on gut microbiome and variation in intestinal bypass lengths will provide insight into the role of bypassed intestine in the effects of gastric bypass on changes in gut microbiota after weight loss surgery. Through correlation with clinical outcomes the investigators will be able to determine any association with weight loss and relief of metabolic disease when the gut microbiota are modified after weight loss surgery.
Approach
Protocol Aim 1: Determine if increasing length of bypassed intestine leads to improved clinical outcomes after gastric bypass.
Primary outcomes will include weight loss and relief of medical comorbidities of obesity, in particular diabetes and dyslipidemia. Secondary outcomes include determining complications that occur such as protein calorie malnutrition, vitamin and micronutrient deficiencies and chronic diarrhea.
1a. Randomization of patients and surgical technique. A total of five groups will be used. The surgical control group will consist of patients having a laparoscopic sleeve gastrectomy as described below under procedure descriptions. The non-surgical control group will include patients undergoing best medical therapy through our medical weight loss program. The other three groups will be randomized through a sealed-envelope method. The assigned group will be in a sealed envelope and the patient will be blinded to the treatment group that they are assigned to. Patients will be randomized to variable lengths of intestinal bypass during performance of a laparoscopic Roux-en-Y gastric bypass. See description of procedure below. These groups will function to examine the impact of increasing lengths of bypassed small intestine through modifications of the BPL length. The following three groups will be utilized:
Surgical Procedure A gastric bypass will be performed using our standard technique. In brief, all procedures will be performed laparoscopically as is standard practice. Specifically at our institution, the gastric pouch will be constructed with a linear stapler approximately 5 cm long and 3 cm wide. The gastrojejunostomy anastomosis will be constructed either with a 25 mm circular stapler or a linear stapler. The linear stapler common gastroenterotomy will be closed in a running 2 layer manner to narrow to approximately 13-15 mm. The jejunojejunostomy will be created with a liner stapler after creation of BPL length of 50 cm, 100 cm or 150 cm and an alimentary limb length of 100 cm which will be connected to the gastric pouch via the gastrojejunostomy. The remaining small bowel, which will represent the common small bowel channel will also be measured. Measurements will be achieved using premeasured markings on a laparoscopic grasper used to handle the small intestine.
Patients undergoing a sleeve gastrectomy will serve as the control group in order to determine the effect that intestinal bypass has on the measured outcomes. The sleeve gastrectomy is performed laparoscopically to resect and remove approximately 80% by volume of the outer portion of the stomach. At our institution, specifically the sleeve gastrectomy is performed using multiple firings of a laparoscopic stapler using a bougie as an intraluminal template for sizing purposes. The bougie is either 36 or 40 French per our usual practice.
2a. Sample collection preoperatively and postoperatively for metabolic and molecular studies.
Sample Collection
Samples will be collected and processed by the OneHealth Biorepository or other on site research laboratory. The following samples will be collected in each patient:
3a. Prospective collection of clinical data. Weight related data will be collected to determine effectiveness of weight loss operations. Weight data collected will include high weight when entering the weight loss surgery program, immediate preoperative weight collected on day of operation and postoperative weights at 1 week, 1 month, 3 months, 6 months and 12 month follow-up appointments. Additional outcomes collected will include presence of diabetes mellitus with glycated hemoglobin (HgbA1C) levels measured preoperatively and at 6 and 12 months postoperatively Remission of diabetes will be considered if the patient is off all anti-diabetic medications with a normal HgbA1C. Presence of preoperative dyslipidemia will also be documented to include abnormalities of LDL cholesterol, HDL cholesterol and triglyceride levels. Remission of dyslipidemia will be considered if preoperative abnormal levels of LDL and HDL cholesterol and triglycerides return to normal in the absence of lipid-lowering agents.
Aim 2: Measure gut hormone changes after increased intestinal bypass during gastric bypass Millipore Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay will be used to investigate a panel of gut hormones including GLP-1, GIP, leptin, PYY, and ghrelin. Plasma from 15 patients from each group (as described above) for a total of 75 total patients will be examined. Hormone levels in the plasma will be measured. Data will be analyzed both for intergroup differences as well as correlation with clinical outcomes will be performed.
Aim 3: miRNA profiling in patients having gastric bypass with variable intestinal bypass lengths 15 patients from each group (as described above) for a total of 75 total patients will be examined. Plasma will be used to perform Affymetrix miRNA arrays to measure expression of all currently known miRNA. Corresponding pathways that miRNA affect will be identified using publicly available databases. Differences in miRNA expression between treatment groups will be compared. Differential levels of expression of miRNA will also be compared to clinical outcomes.
Aim 4: Measure variation in gut microbiome due to increased intestinal bypass during gastric bypass.
Stool samples will be collected as described above. They will be stored in the OneHealth Biorepository or other laboratory until processing. 15 patients from each group (as described above) for a total of 75 total patients will be examined. Composition of microbiota in each group will be determined as previously described. Comparison between treatment groups will be performed. Correlation to clinical outcome variables will be determined
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 cm BP limb length
Procedure: 50 cm BP limb length
100 cm BP limb length
Procedure: 100 cm BP limb length
150 cm BP limb length
Procedure: 150 cm BP limb length
50 cm biliopancreatic limb length
100 cm biliopancreatic limb length
150 cm BP limb length
Weight loss after Variable Biliopancreatic Limb Length Bypass
Evaluation of weight loss after modifications to the length of BP limb length
Time frame: 7 years
Complications after Variable Biliopancreatic Limb Length Bypass
Evaluation of weight loss after modifications to the length of BP limb length
Time frame: 7 years
MicroRNA expression after Variable Biliopancreatic Limb Length Bypass
measurement of circulating microRNA expression in treatment groups
Time frame: 7 years
Gut microbiome changes after Variable Biliopancreatic Limb Length Bypass
measurement of circulating microRNA expression in treatment groups
Time frame: 7 years
Gut enteroendocrine changes after Variable Biliopancreatic Limb Length Bypass
measurement of circulating microRNA expression in treatment groups
Time frame: 7 years
Plan to share: Yes — Only deidentified samples and clinical data with all HIPAA identifiers will be shared with any other researchers
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will only be made available on a case by case data and provided in a deidentified manner
Access criteria: Data must be deidentified and data must be requested from the PI listed
No publications or documents are linked to this record.
Started Nov 2021 (actual). Primary completion is estimated for Mar 2031, 112 months after the start.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 112 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Missouri-Columbia →